The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Did anyone else notice that Abingdon is also listed - Head of Contract Sales, Abingdon Health
I always thought this was the most intresting line in the labroots blurb about Wednesdays Webinar.
"We invite you to our thought-provoking and interactive virtual summit showcasing recently launched technologies, products and solutions supporting the development of diagnostics."
2 superb posts this morning from Sheltie and Captain Stanley that sum up perfectly where we are, where we could end up and the current clues that abound to help our decision making here.
They are neither super rampy or in any way deramps. Entirely sensible with one eye on the immense rewards possible here and the other on the risks that still remain.
Anyone hitting an entirely positive or negative narrative here at the moment should read these posts again.
OCT 28, 2020 : David Wilson Avacta on a panel discussion at 3pm GMT + solo presentation at 5pm GMT sorry for the confusion
OCT 28, 2020 3:00 PM GMT, 8:00 AM PDT, 11:00 AM EDT
Critical design considerations for POC diagnostic test development
The spread of the SARS-COV-2 (COVID-19) pandemic is driving an urgent need for extensive testing, in order to quickly and accurately assess both who is infected, and who has been infected. In order to reach the scale of testing needed, a dual approach of both reverse transcription polymerase chain reaction (RT-PCR) molecular tests and lateral flow based tests needs to be implemented. This session will discuss the design challenges encountered during COVID-19 rapid point of care (POC) diagnostic test development, and the solutions that exist to overcome them.
Learning Objectives:
Understand current COVID-19 diagnostic technologies
Hear why a dual approach of both RT-PCR and lateral flow based tests is needed
Review design challenges you need to be aware of when developing a COVID-19 lateral flow test
Consider what support exists to help developers overcome design challenges
Klaus Hochleitner, PhD Global Technology Lead, Diagnostics, Cytiva
Brendan O'Farrell, PhD President and Co-Founder, DCN Diagnostics
Darren Rowles President and CEO, Sona Nanotech
David Wilson Commercial Director, Diagnostics, Avacta Life Sciences
-------------------------------------
OCT 28, 2020 5:00 PM GMT, 10:00 AM PDT, 1:00 PM EDT
Accelerating rapid test development for COVID-19 through manufacturing scale up and open collaboration
David Wilson Commercial Director, Diagnostics, Avacta Life Sciences
The COVID-19 pandemic has brought unprecedented challenges to the in vitro diagnostics industry and provided a unique opportunity to demonstrate the value of diagnostic testing and a strong diagnostics industry. Diagnostic companies are responding to the demand for the accelerated development of accurate, affordable tests and a rapid, orders-of-magnitude increase in manufacturing capacity through open, pre-competitive collaboration with multiple stakeholders. This includesearly stageIVD companies through to established global corporations, supply chain, governments, regulatory agencies, public and private funding bodies and national healthcare systems.
Learning Objectives:
Highlightspecific examples of the unique challengesbeing faced by the diagnostics industry
Review how a collaborative approach is addressing these challenges
Outline why a stronger diagnostics industry will be one of the enduring legacies of the COVID-19 pandemic"
Opens: 7:00 AM GMT, 12:30pm IST, 3:00pm SGT - Sessions will be available for on-demand viewing immediately following the live broadcast.
Is it interesting that this webinar starts at 7.00am GMT... ?
Also ODX (linked to AVCT regarding manufacturing) have a web presentation same day - results and forecasts..
Am I reading too much into Wednesday... or is something significant about to be announced.. ?
Sorry missed this bit
"Recent events have increased the global focus and commitment on bringing diagnostic tests to market as quickly as possible as well as the challenges the industry has faced in developing and bringing these diagnostic tests to market in exceptional circumstances. A wealth of technology, diverse expertise in areas such as material science, biochemistry, virology as well as a robust supply of critical components are fundamental to the successful development of every test. Optimizing assays and kits for high sensitivity and accuracy is a common goal for all those involved in the development process. The need for close collaboration between diagnostic developers and component and material providers has never been stronger."
https://www.labroots.com/ms/virtual-event/advancing-future-diagnostics
Good reminder thanks : "Critical design considerations for POC diagnostic test development" 28th October
This session includes David Wilson Avacta & Klaus Hochleitner Cytiva - Might be of interest perhaps give some insight in the process taken and if any issues encountered how resolved in getting Avacta LFT ready for clinical validation
https://www.labroots.com/ms/virtual-event/advancing-future-diagnostics/agenda
"OCT 28, 2020 3:00 PM GMT, 8:00 AM PDT, 11:00 AM EDT
Critical design considerations for POC diagnostic test development
SEE ABSTRACT
Klaus Hochleitner, PhD Global Technology Lead, Diagnostics, Cytiva
Brendan O'Farrell, PhD President and Co-Founder, DCN Diagnostics
Darren Rowles President and CEO, Sona Nanotech
David Wilson Commercial Director, Diagnostics, Avacta Life Sciences
Brilliant..thanks.
Correction...it is Cytiva
You may be thinking of BBI on Wednesday....I believe this link is correct but I haven't checked
https://www.labroots.com/ms/virtual-event/advancing-future-diagnostics?s=08
Is there one this week with Cytiva? Can’t find the details.